Table 1 Country malaria treatment policy contexts and status of PDMC policy adoption
Uganda | |
Treatment policy | 1st line treatment for uncomplicated malaria Artemether-lumefantrine (AL) Alternative 1st line treatment is Artesunate-amodiaquine (AS-AQ) 2nd line treatment for uncomplicated malaria Dihydroartemisinin-piperaquine (DP) Severe malaria a) At health facility level: IV artesunate Dihydroartemisinin-piperaquine to be administered at discharge b) Pre-referral treatment at community and lower-level health facilities Rectal artesunate, then continue as in (a) above |
PDMC policy adoption status | MoH has recommended adoption of WHO guidelines on PDMC |
Malawi | |
Treatment policy | 1st line treatment for uncomplicated malaria Artemether-lumefantrine (AL) Dihydroartemisinin-piperaquine (DP) is set to replace AL as first line treatment but has not yet been rolled-out 2nd line treatment for uncomplicated malaria Artesunate-amodiaquine (AS-AQ) Severe malaria IV artesunate Dihydroartemisinin-piperaquine to be administered at discharge |
PDMC policy adoption status | Evidence has been presented to Technical Working Group (TWG) (including case management) and Malaria Advisory Committee MoH has asked Health Service Delivery TWG to review results prior to giving policy approval |
Kenya | |
Treatment policy | 1st line treatment for uncomplicated malaria Artemether-lumefantrine (AL) No planned changes to first line treatment choice 2nd line treatment for uncomplicated malaria Dihydroartemisinin-piperaquine (DP) Severe malaria IV artesunate Artemether-lumefantrine to be administered at discharge |
PDMC policy adoption status | Policy adoption of PDMC has not yet been initiated Stakeholder engagement has commenced |
Benin | |
Treatment policy | 1st line treatment for uncomplicated malaria Artemether-lumefantrine (AL) Dihydroartemisinin-piperaquine (DP) is used in private facilities but is not available in the public system 2nd line treatment for uncomplicated malaria Pyronaridine-artesunate (AP) but not yet in the supply chain Severe malaria IV artesunate Artemether-lumefantrine to be administered at discharge |
PDMC policy adoption status | Policy adoption of PDMC has not yet been initiated Stakeholder engagement has commenced |